ICT&health December 16, 2025
A research team at KAIST has developed a promising new intranasal antiviral platform that uses advanced AI engineering to block rapidly mutating respiratory viruses, including influenza and COVID-19, at their earliest point of entry. The innovation could mark an important step forward in the global fight against respiratory infections, particularly as vaccines alone cannot fully protect against viruses that evolve quickly and in many different forms.
At the core of the new platform is a re-engineered version of interferon-lambda, a naturally occurring immune protein that plays a central role in stopping viral infections in the respiratory tract. Interferon-lambda has long been considered a promising therapeutic candidate, but its clinical usefulness has been limited. When administered in the nose, it breaks...
Today's Sponsors
Today's Sponsor